Obstacles and future of gene therapy for hemophilia. Hemophilia b gene therapy with a highspecificactivity. In fact, multiple recent clinical trials have shown therapeutic, and. Gene therapy in patients with severe hemophilia a video summary of original article dec 28, 2017 aav5factor viii gene transfer in severe hemophilia a s. Human clinical trials are underway to test potential gene therapies for hemophilia. Its not available yet, but after 20 years in development.
Oct 01, 2018 hemophilia b, despite being far less common than hemophilia a, was initially a more attractive target for gene therapy from a molecular perspective. Valoctocogene roxaparvovec is gene therapy designed for the treatment of hemophilia a. Human gene therapy for hemophila draft guidance for industry. Different gene delivery methods are explored, focusing on those currently in clinical trials for gene therapy in hemophilia, and questions about how the body responds to these gene transfer techniques are explained. Such therapy would reduce the need for longterm iv infusions of clotting factors. Advances in therapy gene therapy is currently being investigated as a treatment options for hemophiliacs. The genetic era in hemophilia began in the early 1980s with the isolation and characterization of the genes for human factor viii gitschier et al. Typically, the diseases are identical and, in both, only a modest amount of expression is required to produce a big benefit for the patient, dr. Mar 31, 2017 the future of gene therapy for hemophilia looks bright. Hemophilia b is an xlinked bleeding disorder that results from a deficiency or dysfunction of coagulation factor ix.
The results highlighted knowledge gaps and educational needs related to gene therapy for hemophilia. While gene therapy holds great potential for the treatment of hemophilia, it also faces some obstacles. Hemophilia gene therapies have the potential to provide prolonged, highlevel expression of factor, and limit the need for frequent factor infusion. Hemophilia is an xlinked bleeding disorder caused by deficiency of coagulation factor viii fviii or factor ix fix function due to mutations in the. Pdf the xlinked bleeding disorder hemophilia causes frequent and exaggerated bleeding that can be lifethreatening if untreated. Pdf using factor vii in hemophilia gene therapy bahram. Aav mediated gene therapy for hemophilia b is safe and efficacious. Hemophilia is due to a deficiency in a coagulation factor that results in the inability of the blood to clot efficiently. In hemophilia b gene therapy, either wildtype or padua factor ix with a liverspecific promoter is inserted into the genome of the aav vector and administered via a peripheral vein. Factor levels follow a sawtooth pattern that is seldom in the normal range and falls so low. Advances and challenges for hemophilia gene therapy. Valoctocogene roxaparvovec bmn 270 for hemophilia a. Conventional therapy requires frequent intravenous infusions of the missing coagulation protein factor viii fviii for hemophilia a and factor ix. The concept of gene therapy has sort of been at the.
The hemophilia gene therapy is one of several being tested for conditions including sickle cell anemia and huntingtons disease. The document was approved by the medical and scientific advisory council masac of the national hemophilia foundation nhf on november 21, 2018, and adopted by the nhf board of. The hemophilias are ideally suited for gene therapy because a small increment in blood factor levels. There are existing treatments for hemophilia that require lifelong administration, while gene therapy may offer a onetime treatment to. Even six years ago, gene therapy for hemophilia was a tantalizing promise. Gene therapy aims to achieve this by using two comple.
Dec 06, 2017 gene therapy stops bleeding episodes in hemophilia trial. Interactive features, such as clickable slideshows, popup notes, and icons containing essential information make the learning experience fun and engaging. Hemophilia a is a genetic disease caused by the deficiency of clotting factor viii. After many years, gene therapy in patients with hemophilia has started to show promising results in alleviating symptoms and improving the disease phenotype. Jan 01, 2020 adenoassociated virus aavmediated gene therapy has shown clinical benefit after 1 year of followup for patients with hemophilia a. The initiation of my own independent research career coincided with these landmark discoveries, and my research group, and many others, exploited. Gene therapy for hemophilia explains the complex concepts that underlie gene therapy in simple terms, with colourful medical illustrations and a handy glossary to help explain terminology. Update on clinical gene therapy for hemophilia blood. Human gene therapy for hemophilia draft guidance for industry this guidance document is for comment purposes only. Pdf advances in gene therapy for hemophilia researchgate. The guidance document provides recommendations to stakeholders developing human gene therapy gt products for the treatment of hemophilia.
Given the intrinsic limitations of pst, there is still a need to develop a longterm cure for hemophilia via gene therapy. The report also includes a discussion of the key companies operating in this market. Gene therapy stops bleeding episodes in hemophilia trial. For preclinical research on gene therapy in hemophilia, several wellvalidated small and large hemophilic animal models are available. This guidance provides recommendations on the clinical trial design and related development of coagulation factor viii hemophilia a and ix hemophilia b activity assays. Gene therapy, openlabel, doseescalation study of pf06838435 spk9001 adenoassociated viral vector with human factor ix gene in subjects with hemophilia b brief summary a phase 12, openlabel, nonrandomized, doseescalation study of spk9001 in subjects with hemophilia b. To improve the clinical phenotype of hemophilia, prolonged highlevel expression of clotting factors is needed. This works by providing patients with hemophilia a new working copy of the genes for either factor viii or. The recent success of earlyphase clinical trials for adenoassociated viral aav liverdirected gene therapy for hemophilia b hb demonstrates the potential for gene therapy, in the future, to succeed proteinbased prophylaxis therapy for hb. Federal register human gene therapy for hemophilia. Curing hemophilia would be a signal to the marketplace that gene therapy has hit prime time, says eric faulkner, who studies disruptive medicines at evidera, a consultancy.
The document was approved by the medical and scientific advisory council masac of the national hemophilia foundation nhf on november 21, 2018, and adopted by. Pfizer and spark therapeutics entered into a license agreement. Jul 23, 2019 hemophilia provides an attractive target for gene therapy studies, due to the monogenic nature of these disorders and easily measurable endpoints factor levels and bleed rates. Now, investigators report 2year and 3year safety and efficacy data from 15 patients with severe hemophilia a in a manufacturersponsored phase 12 doseescalation study involving a single infusion of the nonfdaapproved therapy aav5hfviiisq. Technavios hemophilia gene therapy a pipeline analysis report, has been prepared based on an indepth market analysis with inputs from industry experts. Oct, 2017 technavios hemophilia gene therapy a pipeline analysis report, has been prepared based on an indepth market analysis with inputs from industry experts. There are existing treatments for hemophilia that require lifelong administration, while gene therapy may offer a onetime treatment to address the cause of the disease. Now, investigators report 2year and 3year safety and efficacy data from 15 patients with severe hemophilia a in a manufacturersponsored phase 12 doseescalation study involving a single infusion of the nonfda. Hemophilia is a genetic disease that prevents blood from clotting properly leading to prolonged internal and external bleeding. This guidance is intended to assist stakeholders developing human gene therapy gt 1 products for the treatment of hemophilia.
Hemophilia gene therapy is a rapidly evolving therapeutic approach with several phase 3 trials ongoing. Gene therapy for hemophilia article pdf available in hematologyoncology clinics of north america 315. Hemophilia and gene therapy hemophilia occurs when the genes that are vital to producing clotting factors are faulty. Adenoassociated virus aavmediated gene therapy has shown clinical benefit after 1 year of followup for patients with hemophilia a. Results from this study represent a promising step toward making gene therapy a viable treatment option for hemophilia b. Hemophilia may be considered a low hanging fruit for gene therapy because a small increment in blood factor levels 2% of normal significantly improves the. She hails the trial and a second study into gene therapy for people with a resistant form of the rarer haemophilia b as leading the way to a cure for haemophilia. Our gene therapy product candidate etranacogene dezaparvovec amt061 consists of an aav5 viral vector carrying a gene cassette with the padua variant of factor ix fixpadua. Hemophilia is an xlinked monogenic coagulation disorder resulting from a deficiency in coagulation factors in the intrinsic coagulation cascade.
Gene therapy in patients with severe hemophilia a nejm. Hemophilia gene therapy a pipeline analysis report gii. The vector transduces hepatocytes, leading to the production of fix. Quick take gene therapy for factor ix deficiency 01. Hemophilia provides an attractive target for gene therapy studies, due to the monogenic nature of these disorders and easily measurable endpoints factor levels and bleed rates. Hemophilia provides an attractive target for gene therapy studies. Gene therapy for hemophilia a and b could be a permanent cure for people who have these rare, sometimes lifethreatening conditions. Hemophilia has long been one of the disorders thought most likely to be correctible with gene therapy, but previous approaches to deliver the gene have been disappointing, says nhlbi acting director dr. The breakthrough in modern era gene therapy for hemophilia was the publication of the nathwani et al study in 2011. The guidance provides recommendations on the clinical trial design and related development of coagulation factor viii hemophilia a and ix hemophilia b activity assays, including how to address. The best currently available treatments for hemophilia a and b factor viii or factor ix deficiency, respectively require frequent intravenous infusion of highly expensive proteins that have short halflives. Gene therapy information pdf there is excitement in the hemophilia community, both from the side of patients and from physicians and researchers, about the potential benefits of gene therapy for the health and quality of life of hemophiliacs. Human gene therapy for hemophila draft guidance for. Aavbased gene therapy is one of a number of novel approaches for treatment of hemophilia with other gene therapy in vivo and ex vivo.
Gene therapy frequently asked questions pdf gene therapy glossary pdf. Our gene therapy product candidate etranacogene dezaparvovec amt061 consists of an aav5 viral vector carrying a gene cassette with the padua variant of factor ix fixpadua uniqure is now conducting the phase iii hopeb. Advances and challenges for hemophilia gene therapy human. Both hemophilia a and b are caused by defects in single genes. If transferred successfully, the functional gene is intended to provide the correct instructions for the cell to make factor viii or factor ix clotting protein. Gene therapy for hemophilia hematologyoncology clinics. Submit one set of either electronic or written comments on this draft guidance by. Gene therapy for hemophilia is starting to come of age and promises to transform the way patients with this rare blood disease are treated. Dec 06, 2017 the hemophilia gene therapy is one of several being tested for conditions including sickle cell anemia and huntingtons disease.
The haemophilia a gene therapy study took place across multiple centres in the uk and was sponsored by biomarin pharmaceutical. Transferring a form of the gene for factor viii using a viral vector corrected plasma levels of the factor and stopped bleeding episodes for patients with severe hemophilia a, a study shows. This collection of programs provides important information on the science behind gene therapy for hemophilia, the latest safety and efficacy data from clinical trials, and the potential. Takeda demonstrates its longstanding commitment to advancing. Leap forward towards gene therapy cure for haemophilia a. Wfh elearning platform gene therapy for hemophilia. Significant obstacles, however, need to be overcome prior to widespread adoption. Confirmed that certain hemophilia a and hemophilia b gene mutations changes in the genes are linked to inhibitor development. It is the most common type of hemophilia and occurs much more frequently in males.
Mar 11, 2019 gene therapy for hemophilia is starting to come of age and promises to transform the way patients with this rare blood disease are treated. Gene therapy helps patients with hemophilia national. Hemophilia gene therapy is effective and safe blood. Gene therapy corrects factor viii levels in hemophilia a. A gene therapy approach using a socalled antibodydrug conjugate adc conditioning regimen led to safe and sustained production of factor viii fviii in platelets, and prevented joint bleeding in a mouse model of hemophilia a, according to new research the study, nongenotoxic antibodydrug conjugate conditioning enables safe and effective platelet. This study explored knowledge and perceptions about hemophilia gene therapy among the health care team and scientists. Gene therapy for hemophilia a and hemophilia b everyday. Jan 31, 2019 aav vector liver directed gene therapy in hemophilia animal models induces immune tolerance to fviii and fix through induction of factorspecific regulatory t cells treg. All successful, preclinical and clinical studies to date have utilized recombinant adenoassociated viral aav vectors for factor viii or ix hepatocyte transduction. The future of gene therapy for hemophilia looks bright. Quick take gene therapy in patients with severe hemophilia a 02. Breakthroughs in gene therapy for hemophilia ash clinical news. In 2011, a study found adenovirusassociated virus vector expressing human factor ix gene increased fix levels in all participants with hemophilia b.
Several ongoing studies are focused on evaluating various vectors for gene delivery, strategies to enhance transduction efficiency in human hepatocytes, definition of the immune and stress responses to vector administration, and the potential application of genome editing for the treatment. Aav5factor viii gene transfer in severe hemophilia a nejm. One of the interventions for hemophilia currently being explored is gene therapy. The onetime treatments seek to fight the disease by adding correct. In results from the sparkpfizer trial of gene therapy for hemophilia b treatment with spk9001 resulted in a mean steadystate fix coagulant activity of about 33 percent of normal two years after treatment.
131 469 651 165 431 1166 1350 966 218 346 146 1014 485 330 210 1178 877 1536 754 106 1011 1072 1207 492 112 13 612 646 435 1230 1018 170 614 135 870 612 55 1246 1371 808 1125